Daehan Nupharm Co.,Ltd.
Financials
Valuation Metrics
Daehan Nupharm Co.,Ltd.'s Market Cap is ₩729B. At end of 2025 it was ₩943B. Ranked #1413 of 2,405 in KR market (top 59%), #796 of 1,627 on KOSDAQ (top 49%), #155 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 67%) by Market Cap.
Investment Metrics(as of 2026-11-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 72.92B KRW | KR#1,413/2,405 Sec#155/231 |
| Revenue | 211.48B KRW | KR#995/2,405 Sec#56/231 |
| Net Income | 23.93B KRW | KR#640/2,405 Sec#40/231 |
| Total Assets | 281.20B KRW | KR#1,072/2,405 Sec#72/231 |
| Net Assets | 148.94B KRW | KR#1,137/2,405 Sec#79/231 |
| Employees | 397 | KR#612/2,405 Sec#52/231 |
| Value | ||
| P/E | 3.05x | KR#191/2,405 Sec#7/231 |
| P/B | 0.49x | KR#869/2,405 Sec#42/231 |
| PEG | 0.02x | KR#218/2,405 Sec#11/231 |
| P/S | 0.34x | KR#736/2,405 Sec#21/231 |
| EV/EBITDA | 27.70x | KR#1,184/2,405 Sec#71/231 |
| FCF Yield | -47.37% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | 16.07% | KR#278/2,405 Sec#17/231 |
| ROA | 8.51% | KR#393/2,405 Sec#28/231 |
| Op. Margin | 4.59% | KR#1,009/2,405 Sec#73/231 |
| Revenue Growth | 4.95% | KR#1,194/2,405 Sec#117/231 |
| Earnings Growth | 133.79% | KR#329/2,405 Sec#20/231 |
| Financial Health | ||
| Debt Ratio | 88.80% | KR#1,439/2,405 Sec#169/231 |
| Total Debt | 211.23B KRW | KR#501/2,405 Sec#25/231 |
| FCF | -34.54B KRW | KR#2,006/2,405 Sec#196/231 |
| Cash | 15.25B KRW | KR#1,412/2,405 Sec#110/231 |
| Current Ratio | 1.76x | KR#990/2,405 Sec#111/231 |
| Net Debt/EBITDA | 20.19x | KR#1,373/2,405 Sec#99/231 |
| Dividend | ||
| Div. Yield | 1.95% | KR#929/2,405 Sec#46/231 |
| Div. Growth | 0.00% | KR—/2,405 Sec—/231 |
| Performance | ||
| 1Y Return | -21.12% | KR#1,160/2,405 Sec#82/231 |
| 1M Return | -9.12% | KR#943/2,405 Sec#87/231 |
| From 52W High | -35.70% | KR#569/2,405 Sec#37/231 |
| 1Y MDD | -32.36% | KR#303/2,405 Sec#21/231 |
| Trading | ||
| Volume | 5,648 shares | KR#2,038/2,405 Sec#204/231 |
| Trading Value | 28.8M KRW | KR#1,945/2,405 Sec#203/231 |
| Foreign Own. | 0.26% | KR#2,250/2,405 Sec#218/231 |
| Per Share | ||
| EPS | 1,667 KRW | KR#508/2,405 Sec#33/231 |
| BPS | 10,376 KRW | KR#976/2,405 Sec#68/231 |
Company Info
Established in 1984 and listed on KOSDAQ in 2002, Daehan Newpharm is a pharmaceutical company headquartered in Hwaseong-si, Gyeonggi-do. It focuses on specialty pharmaceuticals for metabolic diseases like hypertension and diabetes, as well as digestive ulcer treatments, while strengthening non-reimbursable products such as obesity treatments, vitamins, and immune enhancers. The company diversifies into animal pharmaceuticals, developing pet products and farm environment improvers, and expands its bio business into stem cell-based anti-aging agents and cell therapies.